The consensus headline is seductive: a single infusion that cures a genetic disease for life. Some gene therapies really do approach that. But read past the headline into the patent record and the constraints come into focus.
Here's the single fact the marketing skips: the workhorse delivery vehicle, AAV, can only carry a small gene. Many disease genes are too big to fit. That's not a detail — it decides which diseases the approach can even attempt.
The patents make the engineering burden visible. Genethon's US20230173102A1 covers a synthetic AAV capsid tuned for muscle and nervous-system delivery — meaning you often need a custom-engineered vehicle per tissue. There's no universal delivery truck; you build a new one for each destination, as grants like US11773408B2 for cardiomyopathy illustrate.
Then there's the immune problem the patents keep circling. Publication US20230190956A1 is literally about preventing immune responses to the transduced cells after gene therapy. The body can react to the viral vehicle — which often means you get one shot, because a second dose would be neutralized.
Acknowledge the bull case: for the right rare disease, a durable one-time fix is genuinely transformative, and worth a lot. The science is real and sometimes miraculous.
But the reality check is the economics that follow from the biology. Small cargo, custom vehicles, one-shot dosing, tiny eligible populations — those constraints are why gene therapies carry seven-figure prices and narrow labels. The patents don't hide the limits; they document them. The miracle is real; so is the ceiling.